Research & Development
Aiming to be the Global Pharma Innovator with Competitive Advantage in Oncology, Daiichi Sankyo will focus our research and development resources on certain disease areas through prioritization, such as oncology and cardiovascular-metabolics. The decision making would be driven by diversified viewpoints based on science and business perspectives from our supreme decision-making body – GEMRAD (Global Executive Meeting of Research and Development), to maximize research outcomes.
Daiichi Sankyo established an R&D system at three pivotal sites (Japan, the U.S. and Europe), where we collaborate closely in all the stages from drug discovery to development and manufacture. Furthermore, we have established R&D locations in key emerging markets, Shanghai and Beijing in China. We expect that the roles of these emerging markets would become more important in the future.
Worldwide R&D Organization